In this way, the dual inhibition of the angiotensin receptor AT1 and neprilysin (called ARNI) is a novel therapy that combines a neprilysin inhibitor (sacubitril) that enhances the action of ANP, and a selective antagonist of the AT1 receptor (valsartan) that counteracts the increase in Ang II induced by sacubitril while avoiding the incidence of cough and angioedema caused by ACE inhibitors (Uijl et al., 2020). Here, MME is linked to angioedema.